Kartesia has provided Enterprise Investors portfolio company Nu-Med with a €32m refinancing package.
The package will go towards refinancing all existing financial debt and supporting Nu-Med in its growth plan.
This is the first deal for Kartesia in Poland. Capital for the deal will be drawn from Kartesia Credit Opportunities (KCO) IV and V funds. The firm's fourth fund closed on €870m in October 2017 and offers debt and equity packages of €10-60m to European small and mid-cap companies. KCO V was registered in March 2019 and, according to Unquote Data, is still fundraising.
Enterprise put the asset up for sale, with PwC advising, but did not achieve a sale, according to Unquote sister publication Mergermarket.
Headquartered in Elblag, Poland, Nu-Med is a private operator of four oncology centres in Poland and was founded in 2013.
Kartesia – Giuseppe Mirante (head of DACH credit opportunities).
Nu-Med Group – Paweł Paczkowski (CEO).
Laboratory and imaging diagnostics service is valued at more than EUR 5bn
IK expanded its UK operations to include a local small-cap team headed by partner Tom Salmon in 2020
Asset manager nets a 10.7% IRR on the investment in its listed peer
Romanian cybersecurity company appoints JP Morgan and Morgan Stanley for a dual-track process